Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CNS B cell infiltration in tumefactive anti-myelin oligodendrocyte glycoprotein antibody-associated disease.
Ikeguchi R, Kanda N, Kobayashi M, Masui K, Nitta M, Misu T, Muragaki Y, Kawamata T, Shibata N, Kitagawa K, Shimizu Y. Ikeguchi R, et al. Among authors: masui k. Mult Scler J Exp Transl Clin. 2024 Dec 5;10(4):20552173241301011. doi: 10.1177/20552173241301011. eCollection 2024 Oct-Dec. Mult Scler J Exp Transl Clin. 2024. PMID: 39651331 Free PMC article.
[Renal Pelvic Cancer with Inferior Vena Cava Tumor Thrombus: A Case Report].
Yokozeki H, Sumiyoshi T, Yamane T, Hosomi T, Nakagawa H, Igarashi A, Takeda M, Matsuoka T, Murakami K, Kono J, Kita Y, Masui K, Sano T, Goto T, Sawada A, Teramoto Y, Kobayashi T. Yokozeki H, et al. Among authors: masui k. Hinyokika Kiyo. 2024 Sep;70(9):271-276. doi: 10.14989/ActaUrolJap_70_9_271. Hinyokika Kiyo. 2024. PMID: 39632053 Japanese.
Validity of High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Mobile Tongue Cancer in Terms of the Acute Mucosal Reaction.
Akiyama H, Yoshida K, Kotsuma T, Masui K, Takenaka T, Kano M, Isohashi F, Seo Y, Shimbo T, Murakami N, Mori Y, Kotaki S, Yoshimoto H, Tanaka E, Tselis N, Takácsi-Nagy Z, Yamazaki H, Nakamura S, Tanigawa N, Shimizutani K, Ogawa K, Ariji Y. Akiyama H, et al. Among authors: masui k. Kurume Med J. 2024 Nov 27. doi: 10.2739/kurumemedj.MS7112003. Online ahead of print. Kurume Med J. 2024. PMID: 39603645 Free article.
Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer.
Fukuokaya W, Miki K, Aoki M, Takahashi H, Saito S, Yorozu A, Kikuchi T, Dokiya T, Egawa S; SHIP Collaborative Group. Fukuokaya W, et al. Int J Radiat Oncol Biol Phys. 2024 Nov 16:S0360-3016(24)03584-3. doi: 10.1016/j.ijrobp.2024.11.010. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39551103
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy.
Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Nakamura E, Kaneko T, Kitano G, Motoshima T, Shiraishi, Kira S, Murashima T, Hara H, Matsumura, Nishiyama N, Miyake H, Kitamura H, Uemura H. Fujita K, et al. Among authors: masui k. World J Urol. 2024 Sep 26;42(1):536. doi: 10.1007/s00345-024-05252-2. World J Urol. 2024. PMID: 39325218
415 results